Tools   Select Another Resource Report Type

http://bbmri-eric.eu

BBMRI is a pan-European and internationally broadly accessible research infrastructure and a network of existing and de novo biobanks and biomolecular resources. The infrastructure will include samples from patients and healthy persons, representing different European populations (with links to epidemiological and health care information), molecular genomic resources and biocomputational tools to optimally exploit this resource for global biomedical research. During the past 3 years BBMRI has grown into a 53-member consortium with over 280 associated organizations (largely biobanks) from over 30 countries, making it the largest research infrastructure project in Europe. During the preparatory phase the concept of a functional pan-European biobank was formulated and has now been presented to Member States of the European Union and for associated states for approval and funding. BBMRI will form an interface between specimens and data (from patients and European populations) and top-level biological and medical research. This can only be achieved through a distributed research infrastructure with operational units in all participating Member States. BBMRI will be implemented under the ERIC (European Research Infrastructure Consortium) legal entity. BBMRI-ERIC foresees headquarters (central coordination) in Graz, Austria, responsible for coordination of the activities of National Nodes established in participating countries. BBMRI is in the process of submitting its application to the European Commission for a legal status under the ERIC regulation, with an expected start date at the end of 2011. Major synergism, gain of statistical power and economy of scale will be achieved by interlinking, standardizing and harmonizing - sometimes even just cross-referencing - a large variety of well-qualified, up-to date, existing and de novo national resources. The network should cover (1) major European biobanks with blood, serum, tissue or other biological samples, (2) molecular methods resource centers for human and model organisms of biomedical relevance, (3) and biocomputing centers to ensure that databases of samples in the repositories are dynamically linked to existing databases and to scientific literature as well as to statistical expertise. Catalog of European Biobanks www.bbmriportal.eu Username: guest / Password: catalogue The catalogue is intended to be used as a reference for scientists seeking information about biological samples and data suitable for their research. The BBMRI catalogue of European Biobanks provides a high-level description of Europe''s biobanks characteristics using a portal solution managing metadata and aggregate data of biobanks. The catalogue can be queried by country, by biobank, by ICD-groups, by specimen types, by specific strengths, by funding and more. A search function is available for all data.

Proper citation: Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) (RRID:SCR_004226) Copy   

•   Source: SciCrunch Registry

http://www.partners.org/researchcores/clinical/specimen_BWH.html

The Crimson Biospecimen Core prospectively collects discarded clinical materials matching investigator-defined criteria. Queries are run against real-time data on recently received clinical samples, including ICD.9 codes and results of clinical laboratory testing. Studies using the core must either (1) have an IRB-approved protocol for discarded clinical materials and anonymized information or (2) a protocol to allow collection of discarded samples from patients consented for their study. Collected samples may be additionally processed, aliquotted, or tested per the menu of tests available within the BWH and MGH Clinical Laboratories and Partners Genomics Center. Services: * Collection of discarded clinical specimens including serum, plasma, CSF, urine and microbiological isolates for IRB-approved studies. * Processing or additional clinical testing of collected materials. * Ability to receive consented patient samples for processing and clinical testing. * Online interface to manage collected sample inventories, associated test results, and study users/workgroup per IRB-approval.

Proper citation: Crimson Biospecimen Core (RRID:SCR_004451) Copy   

•   Source: SciCrunch Registry

http://www.biomax.us/

Our robust searchable Tissue Bank database at US Biomax contains normal, non-cancerous disease and cancer samples, just a fraction of total paraffin tissue bank. Use advanced search function to define your search. Some of them have H&E images. Our tissue repository, tissue bank has huge paraffin tissue blocks, a large selection of histology tissue section slides of human cancer, normal tissue, rhesus and cynomolgus normal fresh frozen tissue as well as paraffin blocks and slides. It has also normal human organs in paraffin embedded tissue blocks as well as rhesus and cynomolgus monkey normal organ tissues. Snap frozen (fresh frozen) tissue of rhesus/cynomolgus monkey are also available. We also provide tissue array, custom tissue microarray (with samples you provided or from our tissue bank) as well as OEM services. Other products/services available include tissue microarray, paraffin tissue sections, histology services and quantitative telomerase detection kit.

Proper citation: US Biomax (RRID:SCR_004295) Copy   

•   Source: SciCrunch Registry

http://www.uthouston.edu/uth-big/Projects/BioBank.htm

The University of Texas Health Science Center at Houston (UTHealth) Clinical and Translational Sciences (CCTS) BioBank employs a federated rather than a centralized model which encourages participation by sample owners who are concerned about guaranteeing their ownership of samples and sample information about patients, samples and related clinical data. In a federated model, individual sites agree on shared policies and procedures for data and sample sharing and oversight. Samples remain with and are governed by the contributing principal investigator at each site. The contributing investigator has final authority whether or not to collaborate or to release samples to qualified researchers. The goal of SLED (Sample Location and Enhanced Distribution) is to help researchers overcome two of the biggest obstacles preventing their research from beginning: 1) location of samples and related data, and 2) requesting of samples and related data. Prior to SLED''s inception the existing system was limited to providing links to samples and data and relying on phone calls to sample owners to facilitate sharing. Collaboration between the CTSA Biobank Consortium and the informatics team at the University of Texas School of Biomedical Informatics is ongoing during this effort. The initial design was constructed using best practices offered by NIH, NCI, and other biobank industry leaders to support and to improve synergy and interaction among various research efforts. Through SLED, researchers will be able to search for samples using a variety of criteria including availability, clinical data, consent criteria, patient demographics, patient diagnoses, study data, and sample type at local and national biobank sites.

Proper citation: UTHealth BioBank (RRID:SCR_004570) Copy   

•   Source: SciCrunch Registry

http://www.acceleratedcure.org/impact/repository

A repository of biological samples and data from people with multiple sclerosis, selected other demyelinating diseases, and unaffected controls. The repository not only provides much-needed samples and data to researchers studying MS and other diseases, but also aggregates the results from all of these studies so that they can be analyzed collectively, leading to new findings and breakthroughs. The repository collects blood, DNA, and imaging once per year. The repository currently includes samples and data from over 2,700 subjects with Multiple Sclerosis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis, Optic Neuritis, and Clinically Isolated Syndromes, as well as controls. Blood samples are provided as aliquots as serum, plasma, DNA, RNA, and lymphocytes and each sample is accompanied by more than 40 pages of clinical and epidemiological data contributed by the subject and the enrolling neurologist.

Proper citation: Accelerated Cure Project MS Repository (RRID:SCR_004208) Copy   

•   Source: SciCrunch Registry

http://www.medunigraz.at/en/biobank

Biobank Graz is a non-profit central Medical University of Graz (MUG) service facility that provides the logistics and infrastructure to optimally support MUG research teams in the collection, processing and storage of biological samples and their associated data. In the course of this, special attention is given to sample and data quality and to the protection of the individual rights of patients. Samples from selected patients at the Graz LKH-University Clinical Centre, who have signed an informed consent declaration, are deposited in Biobank Graz. This means that excess tissue and blood samples are collected and placed in storage. The samples are harvested in the course of routine interventions undertaken by the different departments and institutes of the Graz LKH-University Clinical Centre and approved for use in research projects only after the completion of all necessary laboratory and histopathological analyses. No additional material is removed: in other words, there are no associated drawbacks whatsoever for the patients involved. Biobank Graz operates a quality management system according to ISO 9001:2008 and offers the following services for the processing and storage of biological samples and the handling of data: * Consistently high sample quality through the processing of samples using standardized methods in accordance with written working instructions (SOPs) * Efficient use of resources through the building of shared infrastructure and the development of optimized processes * A high degree of reliability provided by the storage of samples in 24/7 - monitored storage systems. * Processing and storage of all data in accordance with data protection legislation. Biobank Graz comprises both population-based and disease-focused collections of biological materials. It currently contains approx. 3.8 mio samples from approx. 1.2 mio patients representing a nonselected patient group characteristic of central Europe. Because the Institute of Pathology was, until 2003, the exclusive pathology service provider for major parts of the province of Styria, including its capital Graz (population approx. 1.2 mio people), samples from all human diseases, treated by surgery or diagnosed by biopsy, are included in the collection at their natural frequency of occurrence and thus represent cancers and non-cancerous diseases from all organs, and from all age groups. The scientific value of the existing tissue collection is, thus, not only determined by its size and technical homogeneity (all samples have been processed in a single institute under constant conditions for more than 20 years), but also by its population-based character. These features provide ideal opportunities for epidemiological studies and allow the validation of biomarkers for the identification of specific diseases and determination of their response to treatment. Prospectively collected tissues, blood samples and clinical data comprise, on the one hand, randomly selected samples from all diseases and patient groups to provide sufficient numbers of samples for the evaluation of the disease-specificity of any gene or biomarker. On the other hand, Biobank Graz adopts a disease-focused approach for selected diseases (such as breast, colon and liver cancers as well as some metabolic diseases) through the collection of a range of different human biological samples of highest quality and detailed clinical follow-up data. Graz Medical University established the Biobank to provide improved and sustainable access to biological samples and related (clinical) data both for its own academic research and for external research projects of academic and industrial partners. It is a major interest of the university to initiate co-operative research projects. Biological samples and data are available to external institutions performing high-quality research projects which comply with the Biobank''s ethical and legal framework according to the access rules (Contact: COO Karine Sargsyan, MD, PhD).

Proper citation: Biobank Graz (RRID:SCR_004245) Copy   

•   Source: SciCrunch Registry

http://www3.marshfieldclinic.org/chg/pages/default.aspx?page=chg_pers_med_res_prj

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 9, 2023. A large collection of biological samples and health information collected for the Personalized Medicine Research Project (PMRP) for use in biological research. Genetic information from 20,000 participants forms a database enabling scientists to study which genes cause disease, which genes predict reactions to drugs, and how environment and genes work together to cause disease. The goal of this project is to learn how to apply genetic science to human health. This knowledge will help researchers develop new medications and diagnostic tests, and will enable physicians to prescribe medications that work best for a particular person. Marshfield Clinic Personalized Medicine Research Project (PMRP) resources currently available: DNA, plasma, serum, questionnaire, electronic medical records to construct phenotypes; ability to recontact subjects for additional information (where they have given consent for recontact); stored pathology specimens collected for clinical purposes; 51 clinically relevant polymorphisms; Illumina 660 quad for ~4200 subjects aged 50+.

Proper citation: Marshfield Clinic Biobank (RRID:SCR_004368) Copy   

•   Source: SciCrunch Registry

https://eyegene.nih.gov

National network of research laboratories for genetic testing of eye disease. They offer testing for affected individuals coupled to registry of clinical information available through patient registry. Large data set for investigators to identify additional genetic risk factors and to explore relationship between genetic disease (genotype) and its clinical manifestation (phenotype).

Proper citation: eyeGENE (RRID:SCR_004523) Copy   

•   Source: SciCrunch Registry

http://www.agre.org/index.cfm

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. A private repository of clinical and genetic information on families with autism. Genetic and clinical data are obtained from families that have more than one family member diagnosed with an Autism Spectrum Disorder. The biological samples, along with the accompanying clinical data, are made available to AGRE-approved researchers worldwide. As they become available, additional family pedigrees will be posted in the online catalog. Cell lines have been established for the majority of families in this collection and serum/plasma is available on a subset of the subjects until stocks are depleted. The diagnosis of autism has been made using the standard Autism Diagnostic Interview-Revised (ADI-R) algorithm and the Autism Diagnostic Observation Scale (ADOS-G). Detailed birth and medical histories (including basic dysmorphology assessments) on children as well as family and medical information for parents and unaffected siblings, are available for nearly all families. DNA, cell lines, serum, plasma and clinical information are made available to AGRE-approved researchers for analysis.

Proper citation: Autism Genetic Resource Exchange (RRID:SCR_004403) Copy   

•   Source: SciCrunch Registry

http://genomics.ucsf.edu/dna-bank

The DNA Bank accepts the clinical samples from projects that have been approved by the Committee on Human Research (CHR). Genomic DNA isolation is performed utilizing standardized and quality controlled Gentra Systems'' PureGene DNA isolation system or Qiagen Kits. The quantity and quality of the genomic DNA isolate is determined by 260/280 UV spectrophotometery. Following isolation and quality assessment, DNA can be aliquoted into a normalized concentration. The preparation of aliquots serves to allow ready distribution of DNA samples to both the client laboratory and their collaborators and to preclude excessive routine freezing and thawing of the primary DNA isolate, a practice which is well known to result in notable degradation of genomic DNA stocks. All samples are stored in alarmed Revco ultra-low freezers at -80����?����?����?��������C. All of the ultra-low freezer units utilized by the DNA Bank are monitored by a temperature sensitive alarm system that provides 24 hour oversight. In the event of a power outage, all freezers are on an emergency back-up electrical generator.

Proper citation: UCSF DNA Bank (RRID:SCR_004248) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/NINDS/?SsId=10

Open resource of biological samples (DNA, cell lines, and other biospecimens) and corresponding phenotypic data to promote neurological research. Samples from more than 34,000 unique individuals with cerebrovascular disease, dystonia, epilepsy, Huntington's Disease, motor neuron disease, Parkinsonism, and Tourette Syndrome, as well as controls (population control and unaffected relatives) have been collected. The mission of the NINDS Repository is to provide 1) genetics support for scientists investigating pathogenesis in the central and peripheral nervous systems through submissions and distribution; 2) information support for patients, families, and advocates concerned with the living-side of neurological disease and stroke.

Proper citation: NINDS Repository (RRID:SCR_004520) Copy   

•   Source: SciCrunch Registry

http://epi.helmholtz-muenchen.de/kora-gen/index_e.php

KORA-gen is infrastructure to provide phenotypes, genotypes and biosamples for collaborative genetic epidemiological research. From all four surveys that have been conducted so far, the following biological material is on hand: genomic DNA, blood serum, blood plasma and EBV immortalized cell lines (form KORA S4 only). These have been extracted from blood samples and are stored in nitrogen tanks and -80 degrees C refrigerators. Genomic DNA from more than 18.000 adult subjects from Augsburg and the surrounding counties is available at present. So far, EBV immortalized cell lines from 1.600 participants are cultivated. To meet the manifold demands of researchers with genetic and molecular questions KORA-gen fulfills the following prerequisites for successful genetic-epidemiological research: * representative samples from the general population, * well characterized disease phenotypes and intermediate phenotypes, * information on environmental factors, * availability of genomic DNA, serum, plasma and urine, as well as EBV immortalized cell lines. In total, four population based health surveys have been conducted between 1984 and 2000 with 18000 participants in the age range of 25 to 74 years, and a biological specimen bank was established in order to enable scientists to perform epidemiologic research with respect to molecular and genetic questions. The KORA study center conducts regular follow-up investigations and has collected a wealth of information on sociodemography, general medical history, environmental factors, smoking, nutrition, alcohol consumption, and various laboratory parameters. This unique resource will be increased further by follow-up studies of the cohort. The assessment of statistical questions covers the definition of the study design and the calculation of statistical power. Furthermore, we offer assistance in data analysis. Kora-gen can be used by external partners. Interested parties can inform themselves interactively via internet about the available data and rules of access. The genotypic data base is a common resource to all partners.

Proper citation: KORA-gen (RRID:SCR_004510) Copy   

•   Source: SciCrunch Registry

http://dbmi.mc.vanderbilt.edu/research/dnadatabank.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on January 11, 2023. BioVU is a research resource providing a View into biology at the level of DNA and other important macromolecules. BioVU has two major components. The first is a repository of DNA samples (extracted from discarded blood samples) that are coded solely by a Research Unique Identifier (RUI) derived from the Medical Record Number (MRN) using a one-way hash function. This is a computer algorithm that creates a transformation of each MRN such that the resulting RUI (which is in this instance is a 512 byte identifier) is unique, and has the property that it is not possible to infer or compute the MRN that generated it. As of early 2009, over 50,000 DNA samples were in the biobank, with new samples being added at the rate of approximately 700 per week. The second component of the resource is the creation of a database known as the Synthetic Derivative which is a collection of de-identified information extracted from VUMC''s electronic clinical information systems, indexed by the same one-way RUI used to track samples, and with content changed by deletion or permutation of all identifiers contained within each record. The Synthetic Derivative search interface is available to Vanderbilt researchers via the StarBRITE research portal created and maintained by the Vanderbilt Institute for Clinical and Translational Research. This user interface enables investigators meeting protocol approval criteria and other user agreement requirements to receive protocol-specific sets of data derived from DNA samples and from the Synthetic Derivative., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Vanderbilt BioVU (RRID:SCR_004632) Copy   

•   Source: SciCrunch Registry

http://www.mnbb.org/

The Michigan Neonatal Biobank (Biobank) is a storage and management facility for The Michigan Department of Community Health''s archive of dried blood spot cards. A 501(c)3 non-profit charitable organization, the Biobank is contracted to serve as the repository for storage and management of the samples in a temperature controlled facility at Wayne State University''s Biobanking Center of Excellence in Tech Town. The Biobank''s roots are planted in the State''s Newborn Screening Program which began in 1965 in the Department of Community Health. Newborn screening is a public health program required by Michigan law to find babies with rare but serious disorders that require early treatment. A few drops of blood taken from the baby''s heel are sent to the State Public Health Laboratory and are tested for 49 disorders. Each year more than 200 Michigan babies are found to have a disorder detected by Newborn Screening. Once screening in the State laboratory is complete, residual dried blood spot samples that are no longer needed for testing are each assigned a unique code which assures anonymity for the sample and its donor. The samples are then sent for storage in the Michigan Neonatal Biobank.

Proper citation: Michigan Neonatal Biobank (RRID:SCR_004541) Copy   

•   Source: SciCrunch Registry

http://www.store-a-tooth.com/

Provia Laboratories Inc. offers Store-A-Tooth, the industry-leading dental stem cell banking service for preserving the stem cells found in baby teeth and wisdom teeth. Store-A-Tooth is a service that provides you the opportunity to store the stem cells inside of teeth that come out. Eligible teeth include baby teeth, wisdom teeth, and other healthy teeth that need to be surgically extracted during the normal course of dental care. Store-A-Tooth has been available since 2006 from dentists across the U.S. At the core of our tooth transport device is the Save-A-Tooth device, which is FDA-approved and ADA accepted for the preservation of avulsed teeth. We use Save-A-Tooth for tooth collection and transport to ensure optimal viability of your sample for processing and cryopreservation. Our laboratory is FDA-registered, CLIA-certified, and AABB-accredited.

Proper citation: Store-a-Tooth Stem Cell Bank (RRID:SCR_004252) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29358&a=31598&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 29, 2016. Project creating a DNA biobank from persons admitted to the neurointensive care unit of the Karolinska University Hospital to study possible genetic influences in traumatic brain injuries (TBI). Serum and cerebrospinal fluid sampled during the subacute phase are also collected. Samples were collected prospectively from clinically well characterized patients to allow for studies of association between candidate genes and clinical outcome parameters or biomarkers for relevant disease processes. The aim is to collect samples from 200-400 individuals. Samples will be collected from TBI patients at up to three different occasions. At first sampling, whole blood, serum and liquor will be collected and at the second and third occasions only serum and liquor.

Proper citation: KI Biobank - TBI (RRID:SCR_005897) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/imm/eims-an-epidemiological-investigation-of-risk-factors-for-multiple-sclerosis

A multi-center population based epidemiological investigation of risk factors for Multiple Sclerosis (MS), where lifestyle- and environmental factors are examined systematically with concurrent genetic information. Newly diagnosed cases of MS in a geographically defined population and randomly chosen controls are identified and asked to answer a questionnaire on lifestyle, previous exposures at work, home and during spare time activities. For both cases and controls blood samples are taken for analysis of putative risk genes since environmental exposures probably contributes to disease only in individuals with certain genotypes. Exposures of interest are different sociodemographic factors, smoking, sunlight exposure, oral contraceptives / hormonal factors, butyrophilin (a milk protein), vaccinations, infections, atopic disease, organic solvents, mineral oils and a number of different psychosocial factors, such as critical lifetime events. Data from more than 1600 cases and 3200 controls are currently collected. (August 2014) The intention is to continue with the data collection over several years in order to analyse how genes and environment interact. The study is a collaboration between different institutions at Karolinska Institutet and neurological centers from 38 different hospitals in Sweden. Sample types * EDTA whole blood * DNA * Plasma * Serum

Proper citation: KI Biobank - EIMS (RRID:SCR_005898) Copy   

•   Source: SciCrunch Registry

http://ki.se/en/imm/gems-genes-and-environment-in-multiple-sclerosis

The study subjects invited to participate is chosen from the Swedish national Multiple Sclerosis registry and will number around 10 000 individuals to be included during two to three years. The same number of matched controls will also be included in the study. A pilot study with around 100 participants was performed during 2009, and the large scale study started in November 2009. Multiple sclerosis (MS) is a neurological disease that affects the central nervous system. It affects young people and the debut age is between 20 and 40 years. The disease comes with exacerbations but further on leads to disability. The incidence in Sweden is around 5 per 100 000 per year and the prevalence is 125 per 100 000 inhabitants. In total there are estimated around 13000 cases in Sweden and today 9000 of them are registered in the Swedish National Multiple Sclerosis register. Sample types * EDTA whole blood * DNA * Plasma Number of sample donors: 5592 (June 2010)

Proper citation: KI Biobank - GEMS (RRID:SCR_005893) Copy   

•   Source: SciCrunch Registry

http://www.geisinger.org/research/centers_departments/genomics/mycode/mycode.html

By collecting and analyzing blood samples from Geisinger''s large patient population, MyCode will help unlock the mysteries of some of the most devastating and debilitating diseases. Blood samples are obtained from patients of certain Geisinger specialty clinics to study specific conditions, such as obesity and cardiovascular disease, and also from patients of Geisinger primary care clinics to provide a representative sample of the regional population. More than 60,000 samples from over 23,000 Geisinger patients have been collected so far, and sample collection is ongoing. MyCode researchers use the blood samples to study the genetic causes of diseases and certain disease-related molecular mediators. Knowledge gained from these studies will allow researchers to pursue innovative approaches to disease prevention, diagnosis and treatment. To be of value for Genomic Medicine research, bio-banked samples must be connected to clinical data: MyCode allows genetic and molecular data about the samples to be connected to medical data in a way that protects patient identity. When a patient agrees to participate in MyCode, blood samples for the MyCode Project are collected during blood draws ordered as part of the patient''s routine medical care. After the sample is drawn and labeled, a staff member from the Weis Center for Research transports the blood to the Geisinger Clinic Genomics Core (GCGC) where it is processed for storage. At this stage, all personal identification markers are removed and the samples are assigned a randomly-selected identification number. A secure key is maintained that allows approved researchers to connect the samples to the clinical data for genomic studies in a way that ensures confidentiality of the information. To maintain confidentiality of MyCode data the code linking the research numbers and the electronic health records are kept in a password-protected files accessible only to MyCode team members. Additionally, all results generated from the samples are reported as a group so that individuals are not identified. The samples are stored indefinitely.

Proper citation: Geisinger Biobank (RRID:SCR_005652) Copy   

•   Source: SciCrunch Registry

http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=556465

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Develop, manufacture and market proprietary, nanocrystalline calcium-phosphate-based biomaterials that promote the repair and regeneration of bone damaged by trauma or disease. ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems.

Proper citation: ETEX Corporation (RRID:SCR_004685) Copy   

•   Source: SciCrunch Registry